Ionis Pharmaceuticals (MEX:IONS) Cyclically Adjusted Revenue per Share: MXN0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
73 GF Score
Price MXN1,150.00
GF Value MXN1,133.83
! 6 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share?

Ionis Pharmaceuticals MEX:IONS 73 Cyclically Adjusted Revenue per Share is MXN0.00 as of Jun. 2026. GuruFocus rates MEX:IONS with a GF Score™ of 73/100 and a GF Value™ of MXN1,133.83. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ionis Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was MXN28.264. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Ionis Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 9.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 17.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Ionis Pharmaceuticals was 23.20% per year. The lowest was -5.50% per year. And the median was 6.65% per year.

As of today (2026-07-30), Ionis Pharmaceuticals's current stock price is MXN1150.00. Ionis Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN0.00. Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ionis Pharmaceuticals was 38.42. The lowest was 4.90. And the median was 12.92.


Ionis Pharmaceuticals  (MEX:IONS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ionis Pharmaceuticals was 38.42. The lowest was 4.90. And the median was 12.92.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 81.74 105.68 73.91 115.83 84.89

Ionis Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.34 101.61 84.89 92.66 0.00

MEX:IONS vs KYMR, PRAX, HALO: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


MEX:IONS
73GF Score
Ionis Pharmaceuticals Inc MEX:IONS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ionis Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=28.264/333.9520*333.9520
=28.264

Current CPI (Jun. 2026) = 333.9520.

Ionis Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 17.384 241.428 24.046
201612 31.687 241.432 43.830
201703 17.447 243.801 23.898
201706 16.368 244.955 22.315
201709 17.264 246.819 23.359
201712 25.985 246.524 35.200
201803 20.935 249.554 28.015
201806 17.976 251.989 23.823
201809 19.801 252.439 26.195
201812 26.068 251.233 34.651
201903 40.734 254.202 53.513
201906 22.437 256.143 29.253
201909 23.113 256.759 30.062
201912 50.549 256.974 65.691
202003 22.429 258.115 29.019
202006 24.107 257.797 31.228
202009 25.312 260.280 32.477
202012 41.257 260.474 52.895
202103 16.206 264.877 20.432
202106 17.758 271.696 21.827
202109 19.390 274.310 23.606
202112 63.921 278.802 76.565
202203 19.956 287.504 23.180
202206 18.983 296.311 21.394
202209 22.640 296.808 25.473
202212 20.847 296.797 23.457
202303 16.483 301.836 18.237
202306 22.573 305.109 24.707
202309 17.527 307.789 19.017
202312 38.357 306.746 41.759
202403 13.627 312.332 14.570
202406 28.273 314.175 30.053
202409 17.732 315.301 18.781
202412 29.918 315.605 31.657
202503 16.963 319.799 17.714
202506 46.683 322.561 48.332
202509 17.994 324.800 18.501
202512 22.545 324.054 23.234
202603 26.916 330.213 27.221
202606 28.264 333.952 28.264

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN0.00 mean?
Ionis Pharmaceuticals (MEX:IONS) has a Cyclically Adjusted Revenue per Share of MXN0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Ionis Pharmaceuticals' current Cyclically Adjusted Revenue per Share is MXN0.00. Overall, Ionis Pharmaceuticals has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to KYMR and PRAX?
Ionis Pharmaceuticals' Cyclically Adjusted Revenue per Share of MXN0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Cyclically Adjusted Revenue per Share is MXN0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Cyclically Adjusted Revenue per Share of MXN0.00. The stock's GF Value™ is MXN1,133.83, compared to a current price of MXN1,150.00 — trading 1.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN0.00. Ionis Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Cyclically Adjusted Revenue per Share is MXN0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 1.4% above its estimated GF Value™ of MXN1,133.83.

Key valuation signals for MEX:IONS:

  • Cyclically Adjusted Revenue per Share: MXN0.00
  • GF Value™: MXN1,133.83 vs. price of MXN1,150.00 (1.4% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
73GF Score

Get the complete analysis for MEX:IONS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN1,133.83
GF Value